Adage Capital Partners Gp, L.L.C. Protagonist Therapeutics, Inc Transaction History

Adage Capital Partners Gp, L.L.C.

$59.7 Billion
Q3 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 718,202 shares of PTGX stock, worth $60.8 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

718,202

Previous 1,092,262 34.25%

Holding current value

$60.8 Million

Previous $60.4 Million 20.97%

% of portfolio

0.08%

Previous 0.11%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$49.7 - $67.42 $18.6 Million - $25.2 Million	-374,060 Reduced 34.25%	718,202 $47.7 Million
Q2 2025 Aug 14, 2025	BUY	$40.89 - $56.37 $30.6 Million - $42.2 Million	748,758 Added 217.98%	1,092,262 $60.4 Million
Q1 2025 May 15, 2025	BUY	$35.09 - $59.76 $12.1 Million - $20.5 Million	343,504 New	343,504 $16.6 Million
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $27 Million - $37.9 Million	-800,451 Reduced 40.0%	1,200,891 $54 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $5.36 Million - $7.57 Million	-217,526 Reduced 9.8%	2,001,342 $69.3 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $20.2 Million - $29.8 Million	927,167 Added 71.78%	2,218,868 $64.2 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $8.31 Million - $13.9 Million	591,701 Added 84.53%	1,291,701 $29.6 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $9.89 Million - $14 Million	-592,711 Reduced 45.85%	700,000 $11.7 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $22.8 Million - $37.1 Million	-1,265,289 Reduced 49.46%	1,292,711 $35.7 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $19.3 Million - $45.5 Million	1,790,955 Added 233.49%	2,558,000 $58.8 Million
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $780,160 - $1.18 Million	-106,000 Reduced 12.14%	767,045 $8.37 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $998,220 - $1.49 Million	-127,000 Reduced 12.7%	873,045 $7.36 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $2.82 Million - $10.2 Million	400,000 Added 66.66%	1,000,045 $7.91 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $3.5 Million - $5.41 Million	150,000 Added 33.33%	600,045 $14.2 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $2.64 Million - $5.57 Million	150,000 Added 49.99%	450,045 $15.4 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $3.24 Million - $12.4 Million	-250,000 Reduced 45.45%	300,045 $5.32 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $1.28 Million - $2.24 Million	-50,000 Reduced 8.33%	550,045 $24.7 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $10.5 Million - $17.1 Million	-550,000 Reduced 47.82%	600,045 $15.5 Million
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $25.3 Million - $34.4 Million	-1,370,555 Reduced 54.37%	1,150,045 $23.2 Million
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $4.87 Million - $7.18 Million	320,600 Added 14.57%	2,520,600 $49.3 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $13.6 Million - $41.4 Million	2,200,000 New	2,200,000 $38.9 Million
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $3.41 Million - $5.63 Million	-500,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$5.99 - $9.1 $3 Million - $4.55 Million	-500,000 Reduced 50.0%	500,000 $3.36 Million
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $8.93 Million - $24.4 Million	-1,056,076 Reduced 51.36%	1,000,000 $8.59 Million
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $21.8 Million - $37 Million	2,056,076	2,056,076 $36.3 Million

Others Institutions Holding PTGX

# of Institutions

296

Shares Held

66.9M

Call Options Held

139K

Put Options Held

40.7K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $4.15B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Protagonist Therapeutics, Inc Transaction History